PTC Therapeutics has abandoned its latest attempt to secure FDA approval for Duchenne muscular dystrophy (DMD) treatment Translarna, after the FDA said it was unlikely to approve the drug based on the ...

PTC Inc. is warning of a critical vulnerability in Windchill and FlexPLM, widely used product lifecycle management (PLM) solutions, that could allow remote code execution. The security issue, ...

PTC Therapeutics is transitioning its growth engine from legacy drugs to new launches like Sephience, targeting rare genetic diseases with high unmet need. Pipeline catalysts, notably Votoplam for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

PTC Industries’ (PTCIL) Q3FY26 EBITDA grew 62% YoY to INR 248mn (-4% YoY) aided by more-than-double sales growth. ATL and TARC registered good top-line growth but margins were under pressure due to ...

With the writing apparently on the wall, PTC Therapeutics has called off its latest bid for FDA approval of its Duchenne muscular dystrophy (DMD) drug Translarna. Late Thursday, PTC revealed that it ...

PTC Inc. (PTC) delivered impressive first-quarter results for fiscal year 2026, significantly surpassing Wall Street expectations. The company’s earnings per share (EPS) came in at $1.92, a 23.87% ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

DENVER (KDVR) — The Colorado Department of Revenue revealed on Wednesday how much eligible Coloradans can receive through its PTC Rebate Program and unveiled a new tax credit for Coloradans with ...

PTC Inc. (PTC) came out with quarterly earnings of $1.64 per share, beating the Zacks Consensus Estimate of $1.22 per share. This compares to earnings of $0.98 per share a year ago. These figures are ...

PTC Therapeutics, Inc. (NASDAQ:PTCT) announced it has gained FDA approval for SEPHIENCE on Monday. “We are excited to have reached this important milestone for those affected by PKU,” said Matthew B.